Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by Dave2008on Feb 04, 2010 8:40pm

547 Views

Post# 16754203

RE: IVUS results timeline

If they show regression, expect this to go through the roof and a bidding war to start. I don't think any pharma wants to miss the opportunity to scoop this up. Two parallel trials right now (see RVX website). This shows plaque regression...it will be the only (and I believe is only) small molecule out there. This is why RVX 208 is so special. Can be taken orally. Anyone correct me but I think I got er down after five years. However I am not writng a book here. Go to website and contact company.

Bullboard Posts

How to navigate the ups and downs of investing in AI